Article

3 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 61, n° 5
pages 775-782 (novembre 2009)
Doi : 10.1016/j.jaad.2009.03.039
accepted : 20 Mars 2009
Original Articles

Clinical genetic testing for familial melanoma in Italy: A cooperative study
 

William Bruno, MD, PhD a, , Paola Ghiorzo, PhD a, , Linda Battistuzzi, MS a, , Paolo A. Ascierto, MD b, Monica Barile, MD c, Sara Gargiulo, PhD a, Francesca Gensini, MD d, Sara Gliori, MD a, Michele Guida, MD e, Maurizio Lombardo, MD f, Siranoush Manoukian, MD g, Chiara Menin, PhD h, Sabina Nasti, PhD a, Paola Origone, PhD a, Barbara Pasini, MD i, Lorenza Pastorino, PhD a, Bernard Peissel, MD g, Maria Antonietta Pizzichetta, MD j, Paola Queirolo, MD k, Monica Rodolfo, PhD g, Antonella Romanini, MD l, Maria Chiara Scaini, PhD m, Alessandro Testori, MD n, Maria Grazia Tibiletti, MD o, Daniela Turchetti, MD p, Sancy A. Leachman, MD q, Giovanna Bianchi Scarrà, PhD a

IMI, the Italian Melanoma Intergroup

a Department of Oncology, Biology, and Genetics, University of Genoa, Genoa, Italy 
b Medical Oncology and Innovative Therapy Unit, National Tumor Institute “Fondazione Pascale,” Naples, Italy 
c Division of Cancer Prevention and Genetics, Chemoprevention, European Institute of Oncology, Milan, Italy 
d Section of Medical Genetics, Department of Pathophysiology, University of Florence, Florence, Italy 
e Medical Oncology Department, National Cancer Institute, Bari, Italy 
f Dermatology, “Ospedale di Circolo,” Varese, Italy 
g Medical Genetics Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy 
h Molecular Immunology and Diagnostic Oncology, Istituto Oncologico Veneto, IRCCS, Padua, Italy 
i Department of Genetics, Biology and Biochemistry, University of Turin, Turin, Italy 
j Division of Medical Oncology, C-Preventive Oncology, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy 
k Department of Medical Oncology A, National Institute for Cancer Research, Genoa, Italy 
l Department of Oncology, Division of Medical Oncology, S. Chiara Hospital, Pisa, Italy 
m Section of Oncology, Department of Oncology and Surgical Sciences, University of Padua, Padua, Italy 
n Melanoma and Muscle-Cutaneous Sarcomas Division, European Institute of Oncology, Milan, Italy 
o Anatomic Pathology Unit, University of Insubria, “Ospedale di Circolo,” Varese, Italy 
p Medical Genetics, Bologna University, “Policlinico S. Orsola Malpighi”, Bologna, Italy 
q Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 

Correspondence to: William Bruno, MD, PhD.
Abstract
Background

The Italian Society of Human Genetics’ (SIGU) recommendations on genetic counseling and testing for hereditary melanoma state that clinical genetic testing can be offered to Italian melanoma families with at least two affected members.

Objective

In the framework of a cooperative study, we sought to establish the frequency of cyclin-dependent kinase inhibitor 2A mutations in melanoma families that underwent clinical genetic counseling and testing in accordance with the SIGU recommendations at 9 centers in different Italian regions.

Methods

Cyclin-dependent kinase inhibitor 2A testing was conducted by direct sequencing and multiplex ligation-dependent probe amplification analysis in melanoma families with at least two affected members.

Results

A total of 33% (68/204) of the families harbored cyclin-dependent kinase inhibitor 2A mutations. In the 145 families with two affected members the mutation frequency was 25%. Three novel mutations, L94P, A86T, and c.407dupG, were identified among the cases and not in 200 controls.

Limitations

We were unable to perform separate analyses for individual centers, as in some cases the number of families was too small.

Conclusions

The availability of clinical genetic testing for melanoma to families with just two affected members in the same branch is justified in Italy in terms of the likelihood of identifying a mutation.

The full text of this article is available in PDF format.

Key words : cyclin-dependent kinase 4 , cyclin-dependent kinase inhibitor 2A , familial melanoma, genetic testing

Abbreviations used : AAD, CDK4 , CDKN2A , GenoMEL, MPM, SIGU



 Supported by the International Melanoma Genetics Consortium 01872 Network of Excellence Grant to Dr Bianchi Scarra’; Dr Scaini is supported by a Fondazione Italiana per la Ricerca sul Cancro (FIRC) fellowship.
 Conflicts of interest: None declared.
 Reprints not available from the authors.

  These authors contributed equally to this study.


© 2009  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline